Pharvaris (NASDAQ:PHVS - Get Free Report) shares saw an uptick in trading volume on Wednesday . 71,000 shares were traded during trading, an increase of 59% from the previous session's volume of 44,547 shares.The stock last traded at $15.00 and had previously closed at $14.83.
Analyst Ratings Changes
Separately, JMP Securities raised their price target on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.
Check Out Our Latest Report on PHVS
Pharvaris Stock Performance
The company has a 50 day moving average price of $16.31 and a 200 day moving average price of $18.72. The company has a market capitalization of $746.70 million, a PE ratio of -5.10 and a beta of -2.84.
Institutional Investors Weigh In On Pharvaris
Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Pharvaris in the 3rd quarter worth approximately $906,000. State Street Corp acquired a new position in Pharvaris in the third quarter valued at approximately $1,000,000. Jane Street Group LLC bought a new position in shares of Pharvaris during the third quarter valued at approximately $526,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Pharvaris during the 3rd quarter worth approximately $57,000. Finally, Barclays PLC bought a new stake in shares of Pharvaris in the 3rd quarter worth approximately $106,000.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Featured Stories
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
